Lateral Flow Immunoassay Validated for Detection of Cryptococcal Antigen
|
By LabMedica International staff writers Posted on 23 Feb 2015 |
|
Image: The CrAg lateral flow assay to detect cryptococcal antigens (Photo courtesy of Immuno-Mycologics).
Cryptococcosis is an important and potentially lethal opportunistic infection in immunocompromised patients, especially in human immunodeficiency virus (HIV) infected and organ transplant patients.
The incidence of the infection in non-HIV immunocompromised patients caused by Cryptococcus neoformans and in immunocompetent patients caused by C. gattii has increased in developed countries.
Medical microbiologists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) compared a lateral flow immunoassay (LFA) to a currently used enzyme immunoassay for detection of cryptococcal antigen in 396 sera and 651 cerebrospinal fluid specimens. The cryptococcal antigen detection was performed in retrospective and prospective sera and CSF specimens collected from March 2010 to August 2012 in patients suspected of cryptococcal infection from the Johns Hopkins Hospital, an academic tertiary care hospital.
The newly developed CrAg lateral flow immunoassay (LFA) (Immuno-Mycologics [IMMY]; Norman, OK, USA) offers a rapid and easy alternative detection platform. The LFA assay detects glucuronoxylomannan (GXM), the major polysaccharide component of the cryptococcal capsule. It is a dipstick sandwich immunochromatographic assay that captures the GXM by gold-conjugated anti-Cryptococcus monoclonal antibodies incorporated on the dipstick membrane. This test was compared with an enzyme immunoassay (EIA) from Meridian Premier (Meridian Biosciences; Cincinnati, OH, USA).
The scientists found 97% concordance between the two assays. The LFA assay detected an additional 22 positives. Overall, the LFA had sensitivity of 100% and specificity of 99.6% for the diagnosis of cryptococcosis. Although reading the LFA result can be subjective, they found that the visible lines suggestive of positive results are usually easy to determine. Easy readability combined with additional advantages of rapid turn-around time of 10-minutes ease of performance, requiring little technical expertise, and limited cost make the LFA an attractive tool for routine laboratory use.
The authors concluded that the IMMY LFA showed better sensitivity in detecting C. neoformans antigen in serum and CSF specimens compared to an EIA method in current use. Because of the enhanced sensitivity, users must be aware of the possibility of false positive results in patients with low clinical suspicion of cryptococcal infection. The LFA is rapid, accurate, easy to perform, and cost-effective, and thus it is attractive for implementation by clinical laboratories for routine patient care testing. The study was published on January 31, 2015, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins University School of Medicine
Immuno-Mycologics
Meridian Biosciences
The incidence of the infection in non-HIV immunocompromised patients caused by Cryptococcus neoformans and in immunocompetent patients caused by C. gattii has increased in developed countries.
Medical microbiologists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) compared a lateral flow immunoassay (LFA) to a currently used enzyme immunoassay for detection of cryptococcal antigen in 396 sera and 651 cerebrospinal fluid specimens. The cryptococcal antigen detection was performed in retrospective and prospective sera and CSF specimens collected from March 2010 to August 2012 in patients suspected of cryptococcal infection from the Johns Hopkins Hospital, an academic tertiary care hospital.
The newly developed CrAg lateral flow immunoassay (LFA) (Immuno-Mycologics [IMMY]; Norman, OK, USA) offers a rapid and easy alternative detection platform. The LFA assay detects glucuronoxylomannan (GXM), the major polysaccharide component of the cryptococcal capsule. It is a dipstick sandwich immunochromatographic assay that captures the GXM by gold-conjugated anti-Cryptococcus monoclonal antibodies incorporated on the dipstick membrane. This test was compared with an enzyme immunoassay (EIA) from Meridian Premier (Meridian Biosciences; Cincinnati, OH, USA).
The scientists found 97% concordance between the two assays. The LFA assay detected an additional 22 positives. Overall, the LFA had sensitivity of 100% and specificity of 99.6% for the diagnosis of cryptococcosis. Although reading the LFA result can be subjective, they found that the visible lines suggestive of positive results are usually easy to determine. Easy readability combined with additional advantages of rapid turn-around time of 10-minutes ease of performance, requiring little technical expertise, and limited cost make the LFA an attractive tool for routine laboratory use.
The authors concluded that the IMMY LFA showed better sensitivity in detecting C. neoformans antigen in serum and CSF specimens compared to an EIA method in current use. Because of the enhanced sensitivity, users must be aware of the possibility of false positive results in patients with low clinical suspicion of cryptococcal infection. The LFA is rapid, accurate, easy to perform, and cost-effective, and thus it is attractive for implementation by clinical laboratories for routine patient care testing. The study was published on January 31, 2015, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins University School of Medicine
Immuno-Mycologics
Meridian Biosciences
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Silver Member
Connectivity Solution
EKF Link
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Latest Microbiology News
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Channels
Clinical Chemistry
view channel
Multi-Omics Study Identifies Blood Marker for MASLD Progression
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality worldwide. As MASLD progresses, fibrosis and liver-related events, including hepatocellular... Read more
Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals
Cardiac troponin is released into the blood when heart muscle is damaged and is widely used as a rapid marker of cardiac injury in adults. In children, interpreting troponin results remains difficult because... Read more
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Molecular Diagnostics
view channel
Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer
For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more
Genomic Screening Expands Detection of Treatable Conditions in Newborns
Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read more
Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed... Read more
Pathology
view channel
AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
Ewing sarcoma is a rare malignant tumor that mainly affects children, adolescents, and young adults. It usually arises in bone but can also develop in soft tissue, where its microscopic appearance may... Read more
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
Estrogen receptor-positive (ER+), HER2-negative advanced breast cancer may require molecular testing to guide treatment selection, with blood-based assays offering a way to identify tumor mutations that... Read more
